Does lisinopril (an ACE inhibitor) cause hypokalemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, lisinopril does NOT cause hypokalemia—it causes HYPERkalemia

Lisinopril, as an ACE inhibitor, blocks aldosterone secretion and reduces potassium excretion by the kidneys, leading to potassium retention and increased serum potassium levels, not decreased levels. 1

Mechanism of Action

Lisinopril inhibits ACE, which decreases angiotensin II production and subsequently reduces aldosterone secretion from the adrenal cortex 1. Since aldosterone normally promotes potassium excretion in the kidneys, blocking it causes potassium retention. The FDA label explicitly states that "the latter decrease [in aldosterone] may result in a small increase of serum potassium" 1.

Expected Potassium Changes

In hypertensive patients with normal renal function:

  • Mean serum potassium increases by approximately 0.1 mEq/L with lisinopril monotherapy
  • About 15% of patients experience increases greater than 0.5 mEq/L 1
  • When combined with hydrochlorothiazide, the mean potassium actually decreases by 0.1 mEq/L (the diuretic effect counteracts the ACE inhibitor effect) 1

Clinical Evidence for Hyperkalemia Risk

The American Heart Association guidelines confirm that hyperkalemia is relatively common in ACE inhibitor-treated patients, particularly those with heart failure or uremia, though increases are generally modest (around 1 mEq/L) 2. In the SOLVD trials, 6.4% of enalapril-treated patients developed potassium levels ≥5.5 mEq/L 2.

The ALLHAT trial demonstrated that year-1 hyperkalemia incidence with lisinopril was 3.6%, significantly higher than chlorthalidone (1.2%) or amlodipine (1.9%) 3.

High-Risk Populations Requiring Monitoring

Monitor serum potassium closely in patients with:

  • Chronic kidney disease or renal insufficiency 2, 1
  • Diabetes mellitus 2, 1
  • Concomitant use of potassium-sparing diuretics (spironolactone, amiloride, triamterene) 1
  • Potassium supplements or salt substitutes 1
  • Dual RAS blockade (with ARBs or aliskiren) 1
  • NSAID use 1

In anuric hemodialysis patients, ACE inhibitors dramatically increase hyperkalemia risk—one study showed 19% developed severe hyperkalemia requiring drug withdrawal 4.

Important Caveat About Combination Therapy

Lisinopril actually attenuates (reduces) the hypokalemia caused by thiazide diuretics 1, 5. This is clinically beneficial, as the potassium-wasting effect of diuretics is counterbalanced by the potassium-retaining effect of ACE inhibitors. This is why combination therapy with hydrochlorothiazide results in near-neutral potassium effects 1.

Monitoring Recommendations

  • Check serum potassium early after initiation of lisinopril 2
  • Monitor periodically during ongoing therapy 1
  • Reduce dietary potassium intake if needed 2
  • Avoid agents that aggravate hyperkalemia (potassium-sparing diuretics, NSAIDs, potassium supplements) 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.